Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation

被引:97
作者
Gerotziafas, G. T.
Petropoulou, A. D.
Verdy, E.
Samama, M. M.
Elalamy, I.
机构
[1] Hop Tenon, Serv Hematol Biol, Assistance Publ Hop Paris, F-75020 Paris 20, France
[2] Univ Paris 06, Fac Med, Paris, France
[3] Hop Hotel Dieu, Serv Hematol Biol, Assistance Publ Hop Paris, F-75181 Paris, France
关键词
fondaparinux; heparin; low-molecular-weight heparin; thrombin generation;
D O I
10.1111/j.1538-7836.2007.02477.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Low-molecular-weight heparins (LMWHs), derived from unfractionated heparin (UFH) by different depolymerization procedures, vary in both their relative abilities to enhance the inhibition of FXa (anti-FXa) and thrombin (anti-FIIa), and in their physicochemical properties. Objective: We aimed to profile the inhibition of thrombin generation induced by bemiparin, enoxaparin, nadroparin, dalteparin and tinzaparin in platelet-rich plasma (PRP), and to compare them with UFH and fondaparinux (a synthetic pentasaccharide that specifically enhances FXa inhibition). Methods: Different LMWHs, UFH or fondaparinux were added to normal PRP. Thereafter, tissue factor-triggered thrombin generation was assessed using the Thrombogram-Thrombinoscope((R)) assay. Results: At equivalent anti-FIIa activity concentrations, LMWHs and UFH exhibited similar inhibitory effects upon thrombin generation. However, when used at equivalent anti-FXa activity concentrations, tinzaparin was significantly more active than the other LMWHs at inhibiting thrombin generation, and had similar activity to that of UFH. Enoxaparin, nadroparin and dalteparin all showed similar inhibitory activities. In these experiments, bemiparin exhibited the lowest inhibitory effect on thrombin generation of all the LMWHs. At 0.1 mu g mL(-1) (0.093 anti-FXa IU mL(-1)), fondaparinux inhibited the rate of thrombin generation by 50%. A 7-fold higher concentration of fondaparinux was required to inhibit the endogenous thrombin potential by 50%. Conclusions: LMWHs have a variable inhibitory effect on thrombin generation in vitro when compared by anti-FXa activity, but are similar when compared by their anti-FIIa activities. The rate of thrombin generation during the propagation phase, rather than the endogenous thrombin potential, is more sensitive to the anticoagulant activity of fondaparinux and the polysaccharide chains of LMWHs possessing only anti-FXa activity.
引用
收藏
页码:955 / 962
页数:8
相关论文
共 50 条
[1]   The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif -: the C-domain [J].
Al Dieri, R ;
Wagenvoord, R ;
Van Dedem, GWK ;
Béguin, S ;
Hemker, HC .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (05) :907-914
[2]   Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial [J].
Antman, EM ;
McCabe, CH ;
Gurfinkel, EP ;
Turpie, AGG ;
Bernink, PJLM ;
Salein, D ;
de Luna, AB ;
Fox, K ;
Lablanche, JM ;
Radley, D ;
Premmereur, J ;
Braunwald, E .
CIRCULATION, 1999, 100 (15) :1593-1601
[3]   COMPARATIVE EFFECTS OF ENOXAPARIN AND UNFRACTIONATED HEPARIN IN HEALTHY-VOLUNTEERS ON PROTHROMBIN CONSUMPTION IN WHOLE-BLOOD DURING COAGULATION, AND RELEASE OF TISSUE FACTOR PATHWAY INHIBITOR [J].
BARA, L ;
BLOCH, MF ;
ZITOUN, D ;
SAMAMA, M ;
COLLIGNON, F ;
FRYDMAN, A ;
UZAN, A ;
BOUTHIER, J .
THROMBOSIS RESEARCH, 1993, 69 (05) :443-452
[4]   Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery [J].
Bara, L ;
Planes, A ;
Samama, MM .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (02) :230-240
[5]   The status of new anticoagulants [J].
Bates, Shannon M. ;
Weitz, Jeffrey I. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (01) :3-19
[6]  
BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457
[7]  
Béguin S, 1999, HAEMOSTASIS, V29, P170
[8]  
BENDETOWICZ AV, 1994, THROMB HAEMOSTASIS, V72, P705
[9]  
BENDETOWICZ AV, 1992, THROMB HAEMOSTASIS, V67, P556
[10]   Low molecular weight heparins: Differences and similarities in approved preparations in the United States [J].
Bick, RL ;
Fareed, J .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 :S63-S66